These underrepresented groups, often in earlier CKD stages, may progress through mechanisms unrelated to sodium retention and volume expansion (Fig. 1), requiring targeted therapies outside of the SGLT2 inhibitor spectrum. This evidence concerns the gene SLC5A2 and chronic kidney disease.